Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe

SAN CARLOS, CA and GOSSELIES, BELGIUM  – October 18, 2018 – Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, and  MaSTherCell S.A. a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO) today announced…

Continue reading "Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe"

Kangstem Biotech selects MaSTherCell for GMP manufacturing of FURESTEM-AD© in Europe

Seoul, Korea and Gosselies, Belgium, October 1, 2018 – Kangstem Biotech, a biotechnology company specializing in developing cell therapies using mesenchymal stem cells derived from human umbilical cord blood, today announces the selection of MaSTherCell as its contract manufacturing partner for its European clinical trial of FURESTEM-AD. MaSTherCell, a subsidiary of Orgenesis Inc. (NASDAQ:ORGS) through Masthercell…

Continue reading "Kangstem Biotech selects MaSTherCell for GMP manufacturing of FURESTEM-AD© in Europe"